Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome

NCT ID: NCT01019356

Last Updated: 2022-01-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-08-31
• Study Completion Date: 2021-07-31

Brief Summary

The investigators hypothesis is that free fatty acids (FFA) accumulation in non fatty tissues would lead to insulin resistance and hyperandrogenism in PCOS women. Accordingly, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great therapeutic option for PCOS as their activation induces transcription factors of gene implicated in fatty acids metabolism.

The aim is to verify if insulin-related hyperandrogenism can be reversed in women having polycystic ovary syndrome following an 8-week treatment with rosiglitazone compared to simple insulin reduction with acarbose.

For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39 kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral glucose tolerance test and a 2-step insulin-glucose clamp.

Detailed Description

Polycystic ovary syndrome (PCOS) is a very common but complex endocrine disorder affecting 6 to 10% of childbearing age women. To diagnose PCOS, women must display two of these three symptoms: clinical or biochemical hyperandrogenism, oligoamenorrhea, and/or echographycally confirmed polycystic ovary. Many studies have also demonstrated that PCOS women are more insulin resistant than control women when matched for body mass index (BMI). Thus, insulin resistance (IR) and secondary hyperinsulinemia would be important premises in the development of PCOS. In fact, the prevalence of type 2 diabetes (T2D) is tripled in PCOS women.

Higher free fatty acid (FFA) concentrations were also observed in the circulation of PCOS women. As FFA accumulates in liver and muscle instead of fat cells, this could be an important cause of IR according to the theory of lipotoxicity. Some indirect evidences are suggesting that FFA accumulation in androgen secreting cells (ovary and adrenal gland) could enhance their androgen production. Based on these findings, our hypothesis is that FFA accumulation in non fatty tissues would lead to IR and hyperandrogenism in PCOS women. Accordingly, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great therapeutic option for PCOS as their activation induces transcription factors of gene implicated in fatty acids metabolism.

The aim is to verify if insulin-related hyperandrogenism can be reversed in PCOS women following an 8-week treatment with rosiglitazone compared to simple insulin reduction with acarbose. For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39 kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral glucose tolerance test and a 2-step insulin-glucose clamp.

Conditions

Polycystic Ovary Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

Rosiglitazone

Lean and obese PCOS women

Group Type: EXPERIMENTAL

Rosiglitazone

Intervention Type: DRUG

4 mg twice daily for 8 weeks orally

Acarbose

Obese PCOS women

Group Type: ACTIVE_COMPARATOR

Acarbose

Intervention Type: DRUG

100 mg three times daily for 8 weeks orally

Control

Obese and lean healthy women evaluated only at baseline

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Rosiglitazone

4 mg twice daily for 8 weeks orally

Intervention Type: DRUG

Acarbose

100 mg three times daily for 8 weeks orally

Intervention Type: DRUG

Other Intervention Names

Avandia; Prandase

Eligibility Criteria

Inclusion Criteria

PCOS :

• Biochemical hyperandrogenism (free testosterone ≥ 50 pmol/l)
• Oligomenorhea (≤ 8 menstrual cycle per year)

Health volunteers :

• Normal menstrual cycle
• Normal levels of free and total testosterone
• No family history with PCOS

Exclusion Criteria

• Diabetes or glucose intolerance
• Current or past use within 3 months of oral contraceptives
• Current or past use within 3 months of medications known to affect insulin sensitivity (metformin, PPARy agonists, b-blockers, thiazides, calcium channel blockers, glucocorticoids, etc.)
• Pulmonary, cardiac, renal, hepatic, neurologic, psychiatric, infectious or neoplastic disease (other than non-melanoma skin cancer)
• Documented or suspected recent (within one year) history of drug abuse or alcoholism
• Use of any investigational drug within three months prior to study onset

Healthy volunteers :

• History of gestational diabetes
• Positive family history for first-degree relative with diabetes
• Disorders linked to insulin resistance (hypertension, dyslipidemia or acanthosis nigricans)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

Jean-Patrice Baillargeon

OTHER

Sponsor Role: lead

Responsible Party

Jean-Patrice Baillargeon

MD

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jean-Patrice Baillargeon, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Université de Sherbrooke

Locations

Université de Sherbrooke

Sherbrooke, Quebec, Canada

Countries

Canada

Other Identifiers

06-075

Identifier Type: -

Identifier Source: org_study_id